Trevi Therapeutics Closes $173M Underwritten Offering, Underwriters Fully Exercise Option
summarizeSummary
Trevi Therapeutics announced the closing of its underwritten public offering, raising a total of $173 million. This amount includes the full exercise by the underwriters of their option to purchase additional shares. This news provides the definitive final amount raised, following earlier announcements on April 16th and 17th regarding the proposed offering, pricing, and initial finalization which indicated a raise of approximately $141 million to $162.3 million. The $173 million capital infusion is material for the company, providing significant liquidity to fund its operations and advance its clinical programs, particularly the Phase 3 trials for Haduvio as highlighted in its recent 10-K. While positive for the company's financial runway, it also confirms the dilutive impact on existing shareholders. Traders will now focus on how this capital is deployed and its potential to accelerate key development milestones.
At the time of this announcement, TRVI was trading at $15.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $5.38 to $16.12. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.